Why the study?
What are the recent advances in pharmacological secondary prevention after a non-cardioembolic ischaemic stroke?
What are the recent advances in pharmacological secondary prevention after a non-cardioembolic ischaemic stroke?
This review summarizes recent advances and highlights critical unanswered questions in the pharmacological secondary prevention of non-cardioembolic ischemic strokes.
Recent advances leave optimal regimens incompletely defined; leaves open critical questions for dedicated trials.
Strokes recur in 6-20% of the patients, most commonly within the first year; after a TIA or minor stroke; most recurrences will occur within the first 90 days. Our ability to identify patients at high risk is poor and most recurrent strokes cannot be explained by traditional risk factors. In 30-45% of the cases the second stroke will be of a different subtype. Moreover, patients are faced with other risks, like cardiac events and cognitive decline. With the population aging, the need for timely and effective secondary prevention strategies is more pressing than ever. This paper summarizes recent advances in pharmacological secondary prevention after a non-cardioembolic ischaemic stroke, and highlights critical questions still in need of answers.
No takes yet. Share an insight, caveat, or question.
Talelli et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: